Chemomab Therapeutics Ltd. American Depositary Share financials
$1.61−1.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$9.6M | -$14.7M | -$25.5M | -$28.5M | -$12.4M |
| Net income | -$9.0M | -$13.9M | -$24.2M | -$27.6M | -$12.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.02 | $-0.04 | $-0.10 | $-0.48 | $-0.24 |
| EBITDA | -$9.5M | -$14.7M | -$25.4M | -$28.5M | -$12.3M |
| Operating cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M |
| Free cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.6M |
| Diluted shares | 510.2M | 359.0M | 235.0M | 56.9M | 51.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.6M | $6.1M | $9.3M | $13.5M | $15.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M |
| Total liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M |
| Shareholders' equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology